TY - JOUR T1 - Transition Rate from EGFR-TKI to Cytotoxic Chemotherapy Patients with EGFR Mutation-positive Lung Adenocarcinoma JF - Anticancer Research JO - Anticancer Res SP - 3127 LP - 3132 VL - 38 IS - 5 AU - YOHEI KAWAGUCHI AU - TETSUYA OKANO AU - MASATOSHI KAKIHANA AU - NAOHIRO KAJIWARA AU - TATSUO OHIRA AU - NORIHIKO IKEDA Y1 - 2018/05/01 UR - http://ar.iiarjournals.org/content/38/5/3127.abstract N2 - Background/Aim: The transition rate from first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) to cytotoxic chemotherapy (Ct) is poor. The prognosis according to treatment sequence and the reasons patients could not shift from first-line EGFR-TKIs to Ct were herein analyzed. Patients and Methods: Overall, 159 epidermal growth factor receptor mutation-positive adenocarcinoma patients were enrolled in this study. Results: The median survival times of EGFR-TKIs combined with Ct and EGFR-TKIs were 59.8 months and 22.5 months, respectively (p<0.001) and of patients who received EGFR-TKIs first and Ct first were 38.8 months and 66.4 months, respectively (p=0.016). The main reasons patients could not make the transition to Ct was worsening of performance status and patient's preference. Conclusion: EGFR-TKIs and Ct lead to a good prognosis in EGFR mutation-positive adenocarcinoma patients. It is necessary to consider the timing when changing the treatment strategy before treatment options are limited. ER -